Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032
The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions.
New York, USA, May 28, 2025 (GLOBE NEWSWIRE) -- Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 | DelveInsight
The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions.
DelveInsight's AI in Precision Medicine Market Insights report provides the current and forecast market analysis, individual leading AI in precision medicine companies' market shares, challenges, AI in precision medicine market drivers, barriers, trends, and key market AI in precision medicine companies in the market.
Key Takeaways from the AI in Precision Medicine Market Report
As per DelveInsight estimates, North America is anticipated to dominate the global AI in precision medicine market during the forecast period.
In the product segment of the AI in precision medicine market, the hardware/software category held the largest revenue share in 2024.
Notable AI in precision medicine companies such as TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and several others are currently operating in the AI in precision medicine market.
In April 2025, Illumina Inc. and Tempus AI, Inc. partnered to accelerate the clinical adoption of next-generation sequencing tests. By combining Illumina's advanced AI technologies with Tempus's extensive multimodal data platform, the collaboration aims to train genomic algorithms and speed up the use of molecular testing in patient care.
In February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic device that uses AI to generate heatmaps to identify small or rare prostatic cancers.
In June 2024, Avicenna.AI, a leading medical imaging AI company, received 510(k) clearance from the FDA for CINA-VCF, an AI-powered triage and notification tool designed to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans.
In March 2024, Bayer and Aignostics entered into a collaboration to advance next-generation precision oncology. Together, they will co-develop a novel target identification platform that utilizes multimodal patient data and cutting-edge AI/ML algorithms to enhance cancer treatment precision.
To read more about the latest highlights related to the AI in precision medicine market, get a snapshot of the key highlights entailed in the Global AI in Precision Medicine Market Report
AI in Precision Medicine Overview
Artificial intelligence (AI) is revolutionizing precision medicine by enabling highly personalized approaches to disease diagnosis, treatment, and prevention. By analyzing vast datasets from genomic sequencing, electronic health records, imaging, and wearable devices, AI algorithms can uncover patterns and biomarkers that are often invisible to human researchers. These insights allow clinicians to identify specific disease subtypes, predict individual patient responses to therapies, and tailor treatments to genetic profiles, thus improving efficacy and reducing adverse effects. In oncology, for instance, AI is helping identify actionable mutations and optimize targeted therapies, bringing more precise interventions to patients.
Beyond diagnosis and treatment, AI also plays a crucial role in accelerating drug discovery and development in precision medicine. Machine learning models can predict drug-target interactions, simulate clinical outcomes, and identify suitable patient cohorts for clinical trials, significantly cutting down timelines and costs. Moreover, AI enhances real-time monitoring of patient health through integration with digital health tools, facilitating timely interventions and adaptive treatment strategies. As data grows more complex and voluminous, AI's ability to synthesize, learn, and adapt offers an indispensable advantage in realizing the full potential of precision medicine.AI in Precision Medicine Market Insights
North America held the largest share of the AI in precision medicine market from 2025 to 2032. This leading position can be attributed to several key factors, including the increasing prevalence of chronic conditions such as cancer, lifestyle-related illnesses like diabetes, and various infectious diseases. The region also benefits from robust R&D initiatives in AI-driven precision medicine, a well-developed healthcare infrastructure.
In addition, major companies in the region are making substantial R&D investments to bring cutting-edge AI-based precision medicine solutions to market. For instance, in April 2024, Prenosis secured FDA De Novo marketing authorization for its Sepsis ImmunoScore™, an AI-powered diagnostic tool that supports precision diagnosis and risk assessment for sepsis. Likewise, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-enabled in vitro diagnostic device that generates heatmaps to detect small or rare prostatic cancers, offering a critical diagnostic aid for pathologists.
As a result of these combined factors, the AI in precision medicine market is expected to experience significant growth in North America throughout the forecast period.
To know more about why North America is leading the market growth in the AI in precision medicine market, get a snapshot of the AI in Precision Medicine Market Outlook
AI in Precision Medicine Market Dynamics
The AI in precision medicine market is undergoing rapid transformation, driven by the convergence of big data analytics, machine learning, and personalized healthcare. Precision medicine focuses on tailoring medical treatment to the individual characteristics of each patient, and AI enables this by analyzing vast datasets from genomic information to electronic health records to identify patterns, predict outcomes, and guide clinical decisions. This has created significant demand for AI-enabled platforms that can support drug discovery, diagnostics, and treatment planning, especially in oncology, rare diseases, and chronic conditions.
Market growth is being accelerated by increasing investments from pharmaceutical companies, biotech startups, and technology giants. These players are leveraging AI to reduce the cost and time of clinical trials, improve target identification, and develop more precise biomarkers. Government initiatives like the U.S. Precision Medicine Initiative and the EU's Digital Health Strategy are also catalyzing adoption by funding R&D and creating regulatory frameworks that support innovation in AI-driven healthcare solutions. As a result, the global market for AI in precision medicine is projected to grow at a strong CAGR through the next decade.
Despite these tailwinds, the market faces several challenges. Data privacy and interoperability remain major hurdles, especially given the sensitive nature of health data and the lack of standardized health IT systems across countries and institutions. Moreover, ethical concerns around algorithmic bias, transparency, and patient consent are prompting calls for tighter regulation and governance. Trust in AI systems remains a key barrier to adoption among healthcare professionals, who often require explainable and clinically validated outputs before integrating AI into routine practice.
Nevertheless, the competitive landscape is vibrant. Major tech firms are partnering with hospitals and research institutions to advance AI-driven care models. Startups focusing on niche applications, such as AI-powered pathology, genomic interpretation, and personalized oncology treatments, are also attracting significant venture capital. As the ecosystem matures, we can expect increasing consolidation and the emergence of integrated platforms that bridge diagnostics, therapeutics, and decision support, further driving market expansion.
Get a sneak peek at the AI in precision medicine market dynamics @ AI in Precision Medicine Market Dynamic Analysis
Report Metrics
Details
Coverage
Global
Study Period
2022–2032
AI in Precision Medicine Market CAGR
~33%
AI in Precision Medicine Market Size by 2032
USD 10.2 Billion
Key AI in Precision Medicine Companies
TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others
AI in Precision Medicine Market Assessment
AI in Precision Medicine Market Segmentation
AI in Precision Medicine Market Segmentation By Product: Hardware/Software and Services
AI in Precision Medicine Market Segmentation By Technology: Deep Learning, Natural Language Processing, and Machine Learning
AI in Precision Medicine Market Segmentation By Application: Drug Discovery & Development and Disease Diagnostics
AI in Precision Medicine Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others
AI in Precision Medicine Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the AI in precision medicine market are set to emerge as the trendsetter explore @ AI in Precision Medicine Companies
Table of Contents
1
AI in Precision Medicine Market Report Introduction
2
AI in Precision Medicine Market Executive Summary
3
Competitive Landscape
4
Regulatory Analysis
5
AI in Precision Medicine Market Key Factors Analysis
6
AI in Precision Medicine Market Porter's Five Forces Analysis
7
AI in Precision Medicine Market Layout
8
AI in Precision Medicine Market Company and Product Profiles
9
KOL Views
10
Project Approach
11
About DelveInsight
12
Disclaimer & Contact Us
Interested in knowing the AI in precision medicine market by 2032? Click to get a snapshot of the AI in Precision Medicine Market Trends
Related Reports
Artificial Intelligence in Drug Commercialization Market
Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others.
Artificial Intelligence in Clinical Trials Market
Artificial Intelligence in Clinical Trials Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others.
Artificial Intelligence In Drug Discovery Market
Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others.
Artificial Intelligence in Medical Imaging Market
Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others.
Artificial Intelligence in Life Sciences Market
Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 https://www.delveinsight.com/medical-devicesSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
AIXA Miner Integrates AI and Clean Energy to Power a New Era of Cloud Mining in 2025
Denver, CO, USA, June 22, 2025 (GLOBE NEWSWIRE) — In a major advancement for the global crypto mining industry, AIXA Miner today announced the expansion of its AI-powered cloud mining platform, now fully supported by green energy sources. The move strengthens AIXA Miner's position as a forward-thinking player in the digital asset space, while making daily crypto income more accessible and more sustainable for users worldwide. As interest in decentralized finance grows and regulatory focus sharpens, 2025 is proving to be a pivotal year for crypto mining. AIXA Miner's cloud-based system offers a hardware-free, AI-optimized, and environmentally conscious mining solution that requires no prior technical knowledge or large capital investment. Bridging Crypto, AI, and Sustainability Designed for beginners and experienced users alike, AIXA Miner enables anyone to start earning daily rewards in leading cryptocurrencies — including Bitcoin, Ethereum, and Litecoin — through its intelligent, cloud-hosted mining architecture. The platform's unique value lies in its combination of: Artificial intelligence , used to dynamically allocate mining resources for optimal output , used to dynamically allocate mining resources for optimal output Clean energy-powered mining farms , cutting environmental impact , cutting environmental impact Free sign-up mining trial , giving newcomers a risk-free entry point , giving newcomers a risk-free entry point Low-cost mining contracts , with flexible durations and terms , with flexible durations and terms Daily payouts and full earnings control, accessible via a secure user dashboard In line with the industry's green transition, AIXA's energy-efficient infrastructure operates in regions with abundant renewable energy sources, aligning with broader ESG standards and carbon neutrality goals. Making Daily Crypto Income Simple AIXA Miner's goal is to eliminate complexity from crypto mining. Users simply register with an email, choose a mining plan (or start with the free trial), and the platform's backend takes care of everything — from resource allocation to performance tracking. With 24/7 cloud uptime, earnings accumulate automatically, and users can withdraw or reinvest anytime. This 'plug-and-earn' experience reflects a growing demand for low-risk, passive income solutions that don't rely on expensive hardware or volatile trading environments. Start Mining in Minutes Go to Register with your email to activate your free trial Choose the crypto you want to mine Let the AI-powered engine begin mining Monitor your earnings in real-time Withdraw anytime, or grow your income with longer-term plans Building a Smarter Mining Future AIXA Miner's 2025 expansion is not just about mining more coins — it's about doing so responsibly, intelligently, and inclusively. With built-in support for multiple global languages and secure wallet integrations, the platform is tailored for a worldwide user base seeking transparent, stable, and eco-friendly mining solutions. About AIXA Miner Founded in 2020, AIXA Miner is a U.S.-based cloud mining platform powered by renewable energy and artificial intelligence. With a presence in over 200 countries and regulatory certifications, the platform delivers secure, daily-yield mining services that are easy to access and designed for long-term sustainability. For more information, visit: [ Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
